New Merck study results raise questions about its COVID-19 pill

partage un lien

2021-11-27 15:06:06 -

https://www.biopharmadive.com/news/merck-molnupiravir-final-results-covid/610597/

WWW.BIOPHARMADIVE.COM

Final trial data for molnupiravir were less convincing than what Merck previously reported and could alter how the FDA views the drug, which will be evaluated at a meeting Tuesday.

0 Commentaires 0 Parts 908 Vue

Commandité

We are 100% funded for October.

Thanks to everyone who helped out. 🥰

Xephula monthly operating expenses for 2024 - Server: $143/month - Backup Software: $6/month - Object Storage: $6/month - SMTP Service: $10/month - Stripe Processing Fees: ~$10/month - Total: $175/month

Please Donate Here